Renishaw Diagnostics Enables Customised Multiplex Assays for Precious Research Samples

GLASGOW, Scotland, February 28, 2011 - Renishaw Diagnostics Ltd, a world leading provider of trace
level detection technologies based on the exploitation of surface enhanced
Raman scattering (SERS) and surface enhanced resonance Raman scattering
(SERRS), for research and molecular diagnostics applications, today announced
the launch of its first research use only (RUO) multiplex assay system which
allows precious research samples to be 'screened' for 10 or more 'targets',
from a single sample.

Jim Greaves, Head of Marketing said "We are very excited about
this product launch and delighted to see the results of our R&D efforts
coming to market. This product will bring a new dimension to the work of many
scientists across a range of disciplines, offering them a very sensitve,
specific and flexible tool to screen for numerous targets in a single assay.
The RUO product launch is a truly transformative technology introduction, in
advance of our fully regulated RenDxTM platform for human diagnostics that is
in advanced stages of development. We have presented the results of some of
our research with collaboration partners at a number of scientific
conferences worldwide and received excellent feedback from healthcare
providers."

The RenDx(TM) RUO multiplex assay system is a novel platform
that allows researchers to generate rapid, multiplex screens for their own
targets of interest. Using patented technologies and supported by a team of
field- and laboratory-based application specialists, the RenDx(TM) RUO system
can be configured to support customers own individual research.

.

The 3-stage process utilises established extraction and
amplification platforms and is fully compatible with standard laboratory
techniques and equipment. This makes the step up to high sensitivity
multiplex detection simple and seamless.

The RenDx(TM) RUO system has a number of advantages over
existing screening methods, including:

    - Multiplex analysis - up to 10 targets from a single sample
    - High sensitivity and specificity
    - Rapid analysis - sample to result within hours
    - Culture independent - analysis direct from the sample
    - Sample matrix independent - simply extract DNA/RNA from any
      biological sample

and this transformative technology is also applicable to a
wide range of research interests such as:

    - Clinical research - e.g. for multiple infectious disease
      targets in humans and animals
    - Pharmaceutical - e.g. biomarkers for antibiotic resistance
    - Food & drink - e.g. pathogens; genetically modified
      ingredients
    - Environmental - e.g. water monitoring

The platform has 3 components: a reagents kit which contains
the materials required to process 100 assays; a purpose-built robotic sample
processor with a simple touchscreen interface, designed to allow user-free
operation while performing the RenDx(TM) assays; and an analyser utilising a
highly sensitive form of spectroscopy known as surface enhanced resonance
Raman scattering (SERRS) which performs multiplex detection and automated
analysis of a wide range of samples with a high degree of sensitivity and
specificity.

About Renishaw Diagnostics Ltd

Renishaw Diagnostics Ltd, formerly D3 Technologies Ltd, was a
Strathclyde University spin-out before being acquired by the Renishaw Group,
which is a leading global supplier of engineering technologies, medical
devices and Raman spectroscopy systems. It is focused on developing and
commercialising its first in vitro diagnostic (IVD) and clinical research
products, with the goal of establishing Renishaw Diagnostics as the premium
provider of automated, multiplex, high sensitivity molecular diagnostics
products for the detection of human infectious diseases. The Company is based
in Glasgow, Scotland, and further information is available at
www.renishawdiagnostics.com.

For further information, contact: Jim Greaves, Head of Marketing, Jim.greaves at renishawdiagnostics.com, T: +44(0)141-5577900